Cultivating Escheria coli Producer of CAF1 Protein in Weightlessness (Astrovaktsina) - 03.07.18

Overview | Description | Applications | Operations | Results | Publications | Imagery

ISS Science for Everyone

Science Objectives for Everyone
The Cultivating Escheria coli Producer of CAF1 Protein in Weightlessness (Astrovaktsina) studies the effect of spaceflight factors on the processes of biosynthesis, secretion, capsule formation, and the biological properties of the E. coli producer of the genetically engineered CAF1 antigen protein of Yersinia pestis during its exposure to microgravity.
Science Results for Everyone
Information Pending

The following content was provided by G. Y. Scherbakov, M.D., and is maintained in a database by the ISS Program Science Office.
Experiment Details

OpNom:

Principal Investigator(s)
G. Y. Scherbakov, M.D., Biopreparat, Russia

Co-Investigator(s)/Collaborator(s)
Information Pending

Developer(s)
Information Pending

Sponsoring Space Agency
Russian Federal Space Agency (Roscosmos)

Sponsoring Organization
Information Pending

Research Benefits
Information Pending

ISS Expedition Duration
October 2007 - April 2008; April 2009 - September 2010

Expeditions Assigned
16,19/20,21/22,23/24

Previous Missions
Information Pending

^ back to top

Experiment Description

Research Overview
Information Pending

Description
Information Pending

^ back to top

Applications

Space Applications
Incubation in spaceflight conditions followed by selection on Earth may be used as a method for obtaining lines of productive strains with an elevated number of copies of plasmids controlling the synthesis of targeted products. This data is important for developing the biotechnology of molecular vaccines against yersiniosis and other infectious diseases in humans and animals, and also for developing a program of life-support systems for cosmonauts during long-term spaceflights.

Earth Applications
The results of the experiment may be used on Earth to obtain highly pure preparation of V antigen blended with polyhistidine peptide as the main component of a new-generation molecular vaccine against yersiniosis, as well as for the targeted creation of new medicines, including medicine for treating Acquired Immune Deficiency Syndrome and a number of tumor diseases.

^ back to top

Operations

Operational Requirements and Protocols
Information Pending

^ back to top

Decadal Survey Recommendations

Information Pending

^ back to top

Results/More Information

Displaying of working cultures on agar slants to microgravity conditions, and the effect of other orbital flight factors, led recombinant Escherichia coli HB101/pVHB62 to synthesize an increased amount of the target product at a level 30% ± 10% greater than that of control samples located on Earth (for example, 12.3 mg/ml and 9.8 mg/ml). Lyophilically dried culture samples did not differ in the level of V gene synthesis in the experimental or control cultures.

V-antigen isolated from cells of the recombinant strain Escherichia coli HB101/pVHB62 exposed to microgravity was identical in terms of molecular mass, spectral properties, and immunochemical properties to V341 antigen obtained from control cultures kept on Earth.

^ back to top

Results Publications

^ back to top

Ground Based Results Publications

^ back to top

ISS Patents

^ back to top

Related Publications

^ back to top

Related Websites
Energia - Science Research on the ISS Russian Segment

^ back to top


Imagery